A comparison of two methods to prevent cardiac muscle damage during cardiopulmonary bypass surgery
Not Applicable
- Conditions
- Coronary artery bypass graft surgery.Unspecified complication of cardiac and vascular prosthetic device, implant and graft
- Registration Number
- IRCT2017083035991N1
- Lead Sponsor
- Vice-chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
patients undegoing coronary artery bypass and valve graft surgery, informed satisfaction.
Exclusion criteria: diagnosed inflammatory diseases before surgery, acute myocardial infarction, patient dissatisfaction, dialysis-requiring renal failure, ejection fraction less than 15%, second surgery, emergency patients, predictive pulmonary disease patients, cardiomyopathy patients.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac Troponin I. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: ng/ml using enzyme immunoassay.;Serum Lactate. Timepoint: Prior to the Coronary artery bypass graft surgery, Immediate post aortic declamping, At the entrance to the ICU, 6, 12, and 24 hours post entrance to the ICU. Method of measurement: Biochemical analyzer.
- Secondary Outcome Measures
Name Time Method Hemoglobin. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.;Hematocrit. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.;Platelet count. Timepoint: Before operation, after operation and 24 hours after operation. Method of measurement: Hematology analyzer.